172 related articles for article (PubMed ID: 36765792)
1. Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis.
León-Letelier RA; Abdel Sater AH; Chen Y; Park S; Wu R; Irajizad E; Dennison JB; Katayama H; Vykoukal JV; Hanash S; Ostrin EJ; Fahrmann JF
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765792
[TBL] [Abstract][Full Text] [Related]
2. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma.
Fahrmann JF; Tanaka I; Irajizad E; Mao X; Dennison JB; Murage E; Casabar J; Mayo J; Peng Q; Celiktas M; Vykoukal JV; Park S; Taguchi A; Delgado O; Tripathi SC; Katayama H; Soto LMS; Rodriguez-Canales J; Behrens C; Wistuba I; Hanash S; Ostrin EJ
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626147
[TBL] [Abstract][Full Text] [Related]
3. Kynureninase Promotes Immunosuppression and Predicts Survival in Glioma Patients: In Silico Data Analyses of the Chinese Glioma Genome Atlas (CGGA) and of the Cancer Genome Atlas (TCGA).
Pérez de la Cruz G; Pérez de la Cruz V; Navarro Cossio J; Vázquez Cervantes GI; Salazar A; Orozco Morales M; Pineda B
Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986469
[TBL] [Abstract][Full Text] [Related]
4. KYNU as a Biomarker of Tumor-Associated Macrophages and Correlates with Immunosuppressive Microenvironment and Poor Prognosis in Gastric Cancer.
Shen K; Chen B; Yang L; Gao W
Int J Genomics; 2023; 2023():4662480. PubMed ID: 37954130
[TBL] [Abstract][Full Text] [Related]
5. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases.
Harden JL; Lewis SM; Lish SR; Suárez-Fariñas M; Gareau D; Lentini T; Johnson-Huang LM; Krueger JG; Lowes MA
J Allergy Clin Immunol; 2016 Jun; 137(6):1830-1840. PubMed ID: 26725996
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
Iuchi K; Tasaki Y; Shirai S; Hisatomi H
Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
[TBL] [Abstract][Full Text] [Related]
9. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
11. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.
Namani A; Cui QQ; Wu Y; Wang H; Wang XJ; Tang X
Oncotarget; 2017 Sep; 8(41):69847-69862. PubMed ID: 29050246
[TBL] [Abstract][Full Text] [Related]
12. KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors.
Li Y; Wang M; Zhao L; Liang C; Li W
Heliyon; 2023 Jun; 9(6):e17216. PubMed ID: 37383199
[TBL] [Abstract][Full Text] [Related]
13. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
14. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
16. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
[TBL] [Abstract][Full Text] [Related]
17. A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer.
Liu Y; Feng X; Lai J; Yi W; Yang J; Du T; Long X; Zhang Y; Xiao Y
J Cell Mol Med; 2019 Oct; 23(10):6700-6707. PubMed ID: 31332944
[TBL] [Abstract][Full Text] [Related]
18. The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment.
Taguchi K; Yamamoto M
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375248
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
